- Title: Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial data
- Date: 8th August 2023
- Summary: COPENHAGEN, DENMARK (FILE - MARCH 6, 2023) (REUTERS) VARIOUS OF FLAGS WITH DANISH MULTINATIONAL PHARMACEUTICAL COMPANY, NOVO NORDISK'S LOGO ON THEM OUTSIDE THE COMPANY'S COPENHAGEN OFFICE VARIOUS OF SIGNS OUTSIDE OFFICES VARIOUS OF EXTERIORS OF NOVO NORDISK NOVO NORDISK LOGO VARIOUS OF BANNER HANGING ON EXTERIOR OF OFFICES VARIOUS OF OFFICES NOVO NORDISK LOGO ON SIGN NOVO NORDISK OFFICES
- Embargoed: 22nd August 2023 12:20
- Keywords: Denmark Novo Nordisk Wegovy cardiovascular health obesity
- Location: COPENHAGEN, DENMARK
- City: COPENHAGEN, DENMARK
- Country: Denmark
- Topics: Europe,Health/Medicine
- Reuters ID: LVA001309408082023RP1
- Aspect Ratio: 16:9
- Story Text: Novo Nordisk said on Tuesday (August 8) its obesity drug Wegovy reduced the risk of a major cardiovascular event like a stroke by 20% in overweight or obese people with a history of heart disease, exceeding expectations from a key late-stage trial.
The large-scale trial called SELECT involved 17,500 patients and started almost five years ago testing if the weekly injection has medical benefits.
The news sent shares in Europe's second-most valuable listed company after LVMH up more than 15%.
Ahead of the eagerly-awaited data, investors and analysts told Reuters they expected that a risk reduction of between 15% and 17% or more would be considered a positive result for the increasingly popular drug.
Showing a clear medical benefit clear, in addition to weight loss, is seen as critical for the Danish drugmaker's hopes of moving beyond Wegovy's image as a lifestyle drug.
(Production: Tom Little) - Copyright Holder: FILE REUTERS (CAN SELL)
- Copyright Notice: (c) Copyright Thomson Reuters 2023. Open For Restrictions - http://about.reuters.com/fulllegal.asp
- Usage Terms/Restrictions: None